Tilray (TLRY) has been one of the most volatile stocks in the cannabis sector compared to Canopy Growth (WEED), Aurora Cannabis (ACB), and Cronos Group (CRON). The company has a low float compared to its peers (HMMJ), which makes it riskier for investors.
As of February 12, analysts’ consensus target price for Tilray was $131, which was nearly 3% higher from $127 in January. The company’s median target price was lower than the mean target price at $120 in February, which remained largely unchanged from a month ago. On February 12, the company closed at $75.9. The current mean target price would translate into an upside of ~72.8% if the current price converged with the target.
In the above chart, six analysts covered Tilray stock and had an overall “buy” recommendation. None of the analysts had a “strong buy” on the stock. Three analysts recommended a “buy,” three analysts recommended a “hold,” and none of the analysts recommended a “sell.”
Next, we’ll discuss analysts’ recommendations for Aphria.